Skip to content

Rapid Micro Biosystems RPID Fair Value Adjustment Of Warrants

Fair Value Adjustment Of Warrants at other companies

Biodesix, Inc. logo
Biodesix, Inc.BDSX
$200K

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Cash & equivalents$14.1M-26.8%
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%
Free cash flow-$15.5M-64.7%

Valuation

See full
Market cap$86.19M-43.8%
Enterprise value$95.86M-31.7%
P/S2.5×-2.6×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's fair value adjustment of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's fair value adjustment of warrants?
Rapid Micro Biosystems (RPID) reported fair value adjustment of warrants of -$70K in Q1 2026.
What does fair value adjustment of warrants mean?
This represents the periodic change in the fair value of outstanding warrant liabilities that are marked-to-market through the income statement. Fluctuations in this metric are driven by changes in the company's stock price, volatility, and time to expiration. It highlights non-operating volatility that can significantly impact reported net income without affecting cash flow.